Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aripiprazole

FDA-approved product (tablet, oral), marketed as Abilify, Abilify Asimtufii, Abilify Maintena Kit and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Aripiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aggressive behavior
  • Agitation
  • Autism
  • Bipolar disorder
  • Bipolar I disorder
  • Depressive disorder
  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aripiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aripiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

    NCT07810738 · start 2026-10-01

    Registered record
    Registry ID
    NCT07810738
    Conditions
    Late Life Treatment Resistant Depression; Depression - Major Depressive Disorder; Treatment Resistant Depression
    Interventions
    Aripiprazole Augmentation; Bupropion Augmentation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-15
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLate Life Treatment Resistant Depression; Depression - Major Depressive Disorder; Treatment Resistant Depression
    InterventionAripiprazole Augmentation; Bupropion Augmentation
    PhasePhase 2
    Registry statusNot yet recruiting

  • Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)

    NCT07011693 · start 2025-06-20

    Registered record
    Registry ID
    NCT07011693
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    Sertraline; Agomelatine; Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-06-20
    Completion
    2027-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    InterventionSertraline; Agomelatine; Aripiprazole
    PhasePhase 4
    Registry statusNot yet recruiting

  • Measurement of Treatment Effects

    NCT07024303 · start 2025-06-15

    Registered record
    Registry ID
    NCT07024303
    Conditions
    Challenging Behavior; Autism Spectrum Disorder
    Interventions
    Psychotropic medication (at discretion of psychiatrist); Behavioral therapy
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2025-06-15
    Completion
    2027-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChallenging Behavior; Autism Spectrum Disorder
    InterventionPsychotropic medication (at discretion of psychiatrist); Behavioral therapy
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

    NCT06937476 · start 2025-05-08

    Registered record
    Registry ID
    NCT06937476
    Conditions
    Major Depressive Disorder (MDD); Rumination
    Interventions
    Escitalopram; Aripiprazole 5mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2025-05-08
    Completion
    2026-07-16
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD); Rumination
    InterventionEscitalopram; Aripiprazole 5mg
    PhaseNot applicable
    Registry statusActive not recruiting

  • Sequential Multiple Assignment Randomized Trial for Bipolar Depression

    NCT06433635 · start 2024-10-01

    Registered record
    Registry ID
    NCT06433635
    Conditions
    Bipolar I Disorder; Depression
    Interventions
    Cariprazine; Aripiprazole/Escitalopram combination; Quetiapine; Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-10-01
    Completion
    2030-02-28
    Enrolment
    2,726

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder; Depression
    InterventionCariprazine; Aripiprazole/Escitalopram combination; Quetiapine; Lurasidone
    PhasePhase 4
    Registry statusActive not recruiting

  • A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia

    NCT06589817 · start 2024-10

    Registered record
    Registry ID
    NCT06589817
    Conditions
    Acute Schizophrenia
    Interventions
    Hydrochloride Carliprazine capsules; Aripiprazole tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2024-10
    Completion
    2026-12
    Enrolment
    376

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Schizophrenia
    InterventionHydrochloride Carliprazine capsules; Aripiprazole tablets
    PhasePhase 3
    Registry statusNot yet recruiting

  • Psychoeducational Group for Depression

    NCT06467474 · start 2024-03-01

    Registered record
    Registry ID
    NCT06467474
    Conditions
    Major Depressive Disorder (MDD
    Interventions
    PEG-D program; TAU
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-03-01
    Completion
    2026-12-01
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD
    InterventionPEG-D program; TAU
    PhaseNot applicable
    Registry statusRecruiting

  • C-Cog in Early Course Schizophrenia Study

    NCT05662306 · start 2024-01-23

    Registered record
    Registry ID
    NCT05662306
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole Lauroxil; Computerized cognitive and functional skills training
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2024-01-23
    Completion
    2025-03-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole Lauroxil; Computerized cognitive and functional skills training
    PhasePhase 4
    Registry statusTerminated

  • Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

    NCT06060886 · start 2023-11-01

    Registered record
    Registry ID
    NCT06060886
    Conditions
    Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis
    Interventions
    Aripiprazole; Paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-11-01
    Completion
    2025-12-31
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders +3 more
    InterventionAripiprazole; Paliperidone
    PhasePhase 4
    Registry statusUnknown

  • Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)

    NCT04812379 · start 2021-04-07

    Registered record
    Registry ID
    NCT04812379
    Conditions
    Bipolar Disorder I
    Interventions
    Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-04-07
    Completion
    2024-06-21
    Enrolment
    535

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder I
    InterventionAbilify prolonged release aqueous suspension for IM injection (Aripiprazole)
    PhaseNot recorded
    Registry statusCompleted

  • Treating Negative Affect in Low Back Pain Patients

    NCT04747314 · start 2021-03-31

    Registered record
    Registry ID
    NCT04747314
    Conditions
    Chronic Low Back Pain; Negative Affectivity
    Interventions
    Antidepressant; Enhanced Fear Avoidance Rehabilitation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-03-31
    Completion
    2024-12-20
    Enrolment
    308

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Low Back Pain; Negative Affectivity
    InterventionAntidepressant; Enhanced Fear Avoidance Rehabilitation
    PhasePhase 2
    Registry statusCompleted

  • Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition

    NCT05532254 · start 2021-02-14

    Registered record
    Registry ID
    NCT05532254
    Conditions
    Healthy Subjects
    Interventions
    Aripiprazole 10 mg tablet; Abilify® 10 mg tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-02-14
    Completion
    2021-03-11
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionAripiprazole 10 mg tablet; Abilify® 10 mg tablet
    PhasePhase 1
    Registry statusCompleted

  • Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    NCT04312503 · start 2020-07-13

    Registered record
    Registry ID
    NCT04312503
    Conditions
    Schizophrenia
    Interventions
    Lurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-13
    Completion
    2022-10-31
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone; aripiprazole, olanzapine, quetiapine or risperidone
    PhaseNot recorded
    Registry statusCompleted

  • RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

    NCT05531591 · start 2019-08-01

    Registered record
    Registry ID
    NCT05531591
    Conditions
    Depression; Dementia; Mild Cognitive Impairment; Treatment Resistant Depression; Major Depressive Disorder; Treatment-Refractory Depression; Late Life Depression; Geriatric Depression
    Interventions
    Aripiprazole Augmentation; Bupropion Augmentation; Switch to bupropion; Lithium Augmentation; Switch to nortriptyline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-08-01
    Completion
    2024-07-31
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Dementia; Mild Cognitive Impairment; Treatment Resistant Depression +4 more
    InterventionAripiprazole Augmentation; Bupropion Augmentation; Switch to bupropion; Lithium Augmentation +1 more
    PhasePhase 4
    Registry statusCompleted

  • A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

    NCT03666715 · start 2018-08-07

    Registered record
    Registry ID
    NCT03666715
    Conditions
    Schizophrenia
    Interventions
    Oral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-08-07
    Completion
    2021-05-31
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOral Antipsychotics (OAPs); Paliperidone Palmitate 1-Month Formulation (PP1M)
    PhaseNot recorded
    Registry statusCompleted